Royalty Pharma plc(RPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RPRX Royalty Pharma plc

休市中 09-25 16:00:00 EDT

58.21

-0.08

-0.14%

盘后58.27

+0.06+0.10%

19:58 EDT

最高58.50	最低57.68	成交量186.95万
今开58.50	昨收58.29	日振幅1.41%
总市值335.84亿	流通市值228.49亿	总股本5.77亿
成交额1.09亿	换手率0.48%	流通股本3.93亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RPRX","market":"US","secType":"STK","nameCN":"Royalty Pharma plc","latestPrice":58.21,"timestamp":1790366400000,"preClose":58.29,"halted":0,"volume":1869507,"hourTrading":{"tag":"盘后","latestPrice":58.27,"preClose":58.21,"latestTime":"19:58 EDT","volume":51878,"amount":3019866.1788,"timestamp":1790380716145,"change":0.06,"changeRate":0.001031,"amplitude":0.001031},"delay":0,"changeRate":-0.0013724481043060268,"floatShares":392526514,"shares":576937187,"eps":1.864321,"marketStatus":"休市中","change":-0.08,"latestTime":"09-25 16:00:00 EDT","open":58.5,"high":58.5,"low":57.68,"amount":108711428.236488,"amplitude":0.014068,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.864321,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790582400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1592280000000,"exchange":"NASDAQ","adjPreClose":58.29,"dividendRate":0.01564,"preHourTrading":{"tag":"盘前","latestPrice":58.29,"preClose":58.29,"latestTime":"09:10 EDT","volume":4534,"amount":264403.352062,"timestamp":1790341810195,"change":0,"changeRate":0,"amplitude":0.058329},"postHourTrading":{"tag":"盘后","latestPrice":58.27,"preClose":58.21,"latestTime":"19:58 EDT","volume":51878,"amount":3019866.1788,"timestamp":1790380716145,"change":0.06,"changeRate":0.001031,"amplitude":0.001031},"volumeRatio":0.5236104433374865,"impliedVol":0.1793,"impliedVolPercentile":0.1793},"requestUrl":"/m/hq/s/RPRX/tweets","defaultTab":"tweets","newsList":[{"id":"1122056429","title":"异动解读｜Royalty Pharma盘中下跌6.4%，标普500指数纳入预期落空引发抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=1122056429","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122056429?lang=zh_cn&edition=full","pubTime":"2026-09-09 00:14","pubTimestamp":1788884098,"startTime":"0","endTime":"0","summary":"9月9日，Royalty Pharma盘中下跌6.4%，报59.875美元/股，成交额1.86亿美元。消息面上，标普500指数于上周五盘后公布最新季度调整结果，此前分析师Melissa Roberts曾将Royalty Pharma列为有望纳入标普500的候选企业之一，公司总市值约368亿美元，远超227亿美元的最低纳入门槛。然而市场预期的纳入未能兑现，资金在盘后及本周一集中抛售，股价自上周五收盘价63.96美元持续回落。制药行业整体同步走弱，礼来跌2.45%，诺华跌13.95%，强生跌2.44%，辉瑞跌1.93%，阿斯利康跌1.68%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"标普纳入预期落空，Royalty Pharma盘中下跌","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119583081","title":"异动解读｜Royalty Pharma盘前下跌5.72%，标普500指数季度调整纳入预期或落空","url":"https://stock-news.laohu8.com/highlight/detail?id=1119583081","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119583081?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:31","pubTimestamp":1788863501,"startTime":"0","endTime":"0","summary":"9月8日，Royalty Pharma盘前下跌5.72%，报60.61美元/股，成交额8.31万美元。消息面上，标普500指数于上周五盘后公布最新季度调整结果。此前分析师Melissa Roberts将Royalty Pharma列为有望纳入标普500的候选企业之一，公司总市值约368亿美元，远高于227亿美元的最低纳入门槛。然而市场预期的纳入未能兑现，资金在盘后及周一盘前集中抛售，股价从上周五收盘价63.96美元大幅回落。制药行业整体同步走弱，礼来跌0.36%，强生跌1.06%，辉瑞跌0.53%，默沙东跌0.73%，阿斯利康跌0.67%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"标普纳入预期落空，Royalty Pharma盘前跳水","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664333811","title":"梯瓦制药（TEVA）与Royalty Pharma（RPRX）合作抗体药物TEV'408迎重大临床突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2664333811","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664333811?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:07","pubTimestamp":1788350836,"startTime":"0","endTime":"0","summary":"金吾财讯 | 梯瓦制药 与Royalty Pharma宣布，双方合作开发的抗白细胞介素-15抗体药物TEV'408在治疗成人乳糜泻的2a期临床试验中取得积极结果。在给药第8周时，与安慰剂组相比，TEV'408在统计学上显著且临床上有效地预防了由麸质诱发的肠道损伤。根据“乳糜泻症状日记”显示，接受TEV'408治疗的患者其胃肠道症状评分明显低于安慰剂组。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305631","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","TEVA","BK4557","LU1983299246.USD","PBE","RPRX","BK4585","BK4007","BK4588","IHE","BK4596","LU2324357040.USD","BK4566","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131861413","title":"Royalty Pharma发布2026年业绩展望：投资组合收入预计34亿至35亿美元，利息支出约3.5亿至3.6亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1131861413","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131861413?lang=zh_cn&edition=full","pubTime":"2026-08-05 19:11","pubTimestamp":1785928260,"startTime":"0","endTime":"0","summary":"Royalty Pharma plc（简称：Royalty Pharma）近日公布了其2026年的业绩展望。根据这份预期，该公司预计其投资组合收入将介于34亿美元至35亿美元之间。与此同时，其利息支出部分则预计在3.5亿美元至3.6亿美元的范围内。这一财务指引为市场投资者提供了关于这家生物制药特许权投资公司未来盈利能力和财务成本的关键参考。通过评估这些数据，分析师们能够更清晰地判断Royalty Pharma在2026年的整体现金流和运营效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PBE","RPRX","IHE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121493350","title":"财报前瞻｜Royalty Pharma plc本季度营收预计小幅增长，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1121493350","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121493350?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:00","pubTimestamp":1785286845,"startTime":"0","endTime":"0","summary":"Royalty Pharma plc将于2026年08月05日发布财报，市场关注其核心版税组合现金流的韧性与里程碑付款节奏对当季收入与利润的影响。市场一致预期显示，本季度Royalty Pharma plc营收预计为6.93亿美元，同比增长1.34%；调整后每股收益预计为1.28美元，同比增长17.74%；息税前利润预计为6.02亿美元，同比下降4.51%。上季度Royalty Pharma plc营收为9.25亿美元，同比增长10.25%；毛利率为131.32%；归属于母公司股东的净利润为2.95亿美元，净利率为46.73%，环比增长37.57%；调整后每股收益为1.30美元，同比增长100.00%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Royalty Pharma plc本季度营收预计小幅增长，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129561583","title":"Royalty Pharma宣布2026年第三季度股息派发","url":"https://stock-news.laohu8.com/highlight/detail?id=1129561583","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129561583?lang=zh_cn&edition=full","pubTime":"2026-07-18 04:17","pubTimestamp":1784319458,"startTime":"0","endTime":"0","summary":"Royalty Pharma plc董事会已批准派发2026年第三季度股息，每股A类普通股股息为0.235美元。此次股息将于2026年9月10日支付给截至2026年8月14日营业结束时登记在册的股东。Royalty Pharma成立于1996年，是生物制药领域特许权使用费的最大收购方，也是行业创新的重要资助者。Royalty Pharma构建了一个多元化的特许权组合，使其有权直接基于行业众多领先疗法的总销售额获得收益支付。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RPRX","IHE","PBE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182801973","title":"财报前瞻 ｜Royalty Pharma plc本季营收预计增64.58%，机构看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1182801973","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182801973?lang=zh_cn&edition=full","pubTime":"2026-04-30 00:15","pubTimestamp":1777479306,"startTime":"0","endTime":"0","summary":"Royalty Pharma plc将于2026年05月06日美股盘前发布新季度财报，市场聚焦组合回报释放与资本配置节奏。看多方认为，公司组合以高毛利的版税现金流为核心，上一季度调整后每股收益1.47美元同比增长27.83%，净利率维持在34.44%，显示盈利质量稳健；在此基础上，本季度营收预测同比增长64.58%、EBIT同比增长108.22%，若落地将推动年度盈利预期上调。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜Royalty Pharma plc本季营收预计增64.58%，机构看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164399930","title":"Royalty Pharma宣布2026年第二季度股息派发方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1164399930","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164399930?lang=zh_cn&edition=full","pubTime":"2026-04-17 20:33","pubTimestamp":1776429212,"startTime":"0","endTime":"0","summary":"Royalty Pharma plc董事会近日通过2026年第二季度股息分配决议，A类普通股每股派息0.235美元。该股息将于2026年6月10日向截至2026年5月15日收盘时登记在册的股东发放。作为1996年成立的全球最大生物制药特许权收购方，Royalty Pharma始终是生物医药创新领域的重要资金支持者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RPRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511692483","title":"Royalty Pharma Plc2024财年实现净利润8.59亿美元，同比减少24.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511692483","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511692483?lang=zh_cn&edition=full","pubTime":"2025-02-15 00:00","pubTimestamp":1739548842,"startTime":"0","endTime":"0","summary":"2月15日，Royalty Pharma Plc公布财报，公告显示公司2024财年净利润为8.59亿美元，同比减少24.32%；其中营业收入为22.64亿美元，同比减少3.86%，每股基本收益为1.92美元。从资产负债表来看，Royalty Pharma Plc总负债78.80亿美元，其中短期债务9.98亿美元，资产负债比为2.32，流动比率为1.44。机构评级：截至2025年2月15日，当前有6家机构对Royalty Pharma Plc目标价做出预测，其中目标均价为40.17美元，其中最低目标价为28.00美元，最高目标价为48.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215000117abcf1af4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215000117abcf1af4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190995950","title":"Royalty Pharma 2024年第四季度调整后每股收益$1.16超出$1.05的预期，销售额$5.94亿未达到$6.78亿的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1190995950","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190995950?lang=zh_cn&edition=full","pubTime":"2025-02-11 20:30","pubTimestamp":1739277028,"startTime":"0","endTime":"0","summary":"Royalty Pharma报告季度每股收益为$1.16，超过分析师一致预期的$1.05，增幅为10.48%。公司报告季度销售额为$5.94亿，未达到分析师一致预期的$6.78亿，相差12.50%。与去年同期销售额$5.96亿相比，下降了0.34%。以上内容来自Benzinga Earnings专栏，原文如下：Royalty Pharma  reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.05 by 10.48 percent. This is a 0.87 percent increase over earnings of $1.15 per share from the same period last year.  The company reported quarterly sales of $594.00 million which missed the analyst consensus estimate of $678.89 mil","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Royalty Pharma 2024年第四季度调整后每股收益$1.16超出$1.05的预期，销售额$5.94亿未达到$6.78亿的预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504449484","title":"特朗普2.0时代即将开启，投资机会如何掘金？","url":"https://stock-news.laohu8.com/highlight/detail?id=2504449484","media":"招商基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504449484?lang=zh_cn&edition=full","pubTime":"2025-01-20 10:36","pubTimestamp":1737340585,"startTime":"0","endTime":"0","summary":"美国候任总统唐纳德·特朗普将于美东时间1月20日12时正式宣誓就任美国第47任总统。特朗普2.0时代即将开启，有哪些投资机会可以布局？值得一提的是，科技股在特朗普任期内表现尤为突出，成为推动美股上涨的主要力量。在特朗普第一个任期内，美元整体表现相对弱势。4年任期内，美元指数累计下跌了10.53%。而纵观全球市场，在特朗普上一任期内，恒生科技指数涨幅超过147%，表现甚至略微优于纳斯达克指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HST","CZR","HOOD","FFIV","ITCI","MARA","JKHY","AGNC","BPMC","AKAM","EA","QID","LULU","PARA","TSLA","ZS","LIN","MKTX","NTRA","FSLR","COST","LECO","ODFL","ORLY","PLTR","CRWD","STX","SAIA","WDC","EXPE","DOX","WBA","NVMI","WYNN","MPWR","NBIX","ROP","EBAY","ROST","MNQmain","AMGN","MDB","TTD","TECH","ISRG","SSNC","AVGO","SQQQ","MCHP","PCTY","PTC","REGN","SIRI","TPG","BK4086","USAW.SI","MRNA","STLD","MNDY","FOXA","KHC","IDXX","EXE","GNTX","MKSI","TSCO","TSEM","EVRG","CPRT","MDLZ","GLPI","TEAM","HLNE","POOL","ICLR","OTEX","AFRM","LNT","ENTG","ARGX","SMCI","TLN","RIVN","OKTA","LSTR","CWST","FSV","CDW","INTC","NWSA","TRMB","ADI","ERIE","LU0053671581.USD","CEG","SWKS","TSYW.SI","HBAN","LSCC","MTSI","ON","BKR","QRVO","JD","ANSS","BK4588","ALNY","BKNG","SNPS","WTFC","Z","ALGN","EQIX","FCNCA","GTLB","GOOGL","LOGI","CBSH","LU1815336091.USD","FTNT","SOFI","TW","DKNG","MANH","NQmain","PDD","FYBR","LU0757428866.USD","RGEN","MEDP","AEP","CSWI","GILD","CTAS","AZN","PAA","SFM","SRPT","SBUX","QLD","COO","ESLT","FOX","BK4561","PEP","INTU","DASH","BK4593","CSGP","FWONK","RPRX","TCOM","BSY","LI","CYBR","CFLT","CHKP","MRVL","APA","COKE","MTCH","ADBE","ONC","BK4550","PCAR","RYAAY","BK4534","SEIC","TTEK","HSIC","BIIB","GEN","QXO","BK4581","PAYX","AMAT","LKQ","FRPT","MSFT","BRKR","ASML","TQQQ","AAL","PFG","DPZ","NVDA","TROW","KDP","NVIW.SI","FER","RKLB","DLTR","LAMR","EWBC","RGLD","NFLX","COIN","NTES","CPB","HOLX","CHTR","CHRD","CDNS","CHDN","NTNX","CG","PNFP","ROIV","USJW.SI","SBAC","ARM","TXN","AXON","BPOP","LPLA","MMYT","ENPH","BMRN","GRAB","ULTA","NTAP","TMUS","AUR","EXAS","CCEP","REG","RVMD","ZM","GEHC","INCY","CTSH","HON","MIDD","PODD","TER","FAST","META","CSCO","JBHT","DDOG","ROKU","BK4585","HTHT","PCVX","CSX","NTRS","MELI","LNW","FTAI","NICE","CHRW","ILMN","LU2065731478.USD","HQY","TTWO","CASY","AMD",".IXIC","RADX","NDSN","NDAQ","DSGX","ALAB","ADSK","WWD","MNST","QQQ","DOCU","INSM","NXPI","PSQ","OLED","GMAB","AAPL","AMZN","QCOM","CME","ERIC","DUOL","CINF","AAON"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2502489855","title":"Royalty Pharma Plc盘中异动 股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502489855","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502489855?lang=zh_cn&edition=full","pubTime":"2025-01-10 22:31","pubTimestamp":1736519476,"startTime":"0","endTime":"0","summary":"北京时间2025年01月10日22时31分，Royalty Pharma Plc股票出现异动，股价急速上涨5.00%。Royalty Pharma Plc股票所在的生物技术行业中，整体跌幅为0.32%。Royalty Pharma Plc公司简介：Royalty Pharma PLC 是生物制药特许权使用费最大的买家。Royal Pharma 收取超过 35 种商业产品的特许权使用费，包括艾伯维和强生的 Imbruvica、Biogen 的 Tysabri、Vertex 的囊性纤维化特许经营权和 10 个开发阶段的候选产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110223116a21d0d6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110223116a21d0d6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","RPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2483385635","title":"Royalty Pharma Plc2024财年第三财季实现净利润5.44亿美元，同比增加654.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483385635","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2483385635?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:01","pubTimestamp":1731600115,"startTime":"0","endTime":"0","summary":"11月15日，Royalty Pharma Plc公布财报，公告显示公司2024财年第三财季净利润为5.44亿美元，同比增加654.40%；其中营业收入为5.65亿美元，同比增加5.41%，每股基本收益为1.22美元。从资产负债表来看，Royalty Pharma Plc总负债77.84亿美元，其中短期债务9.97亿美元，资产负债比为2.32，流动比率为1.54。机构评级：截至2024年11月15日，当前有7家机构对Royalty Pharma Plc目标价做出预测，其中目标均价为41.71美元，其中最低目标价为28.00美元，最高目标价为51.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000221abc189fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000221abc189fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RPRX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.royaltypharma.com","stockEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0581},{"period":"3month","weight":0.0352},{"period":"6month","weight":0.2559},{"period":"1year","weight":0.6679},{"period":"ytd","weight":0.5065}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0069},{"period":"3month","weight":0.0581},{"period":"6month","weight":0.2165},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Royalty Pharma plc于2020年2月6日根据英格兰和威尔士法律注册成立。该公司是生物制药特许权使用费的最大买家，并且是生物制药行业创新的主要资助者。自1996年成立以来，该公司一直是特许权使用费市场的先驱，与来自学术机构，研究医院和非营利组织的创新者（通过中小型生物技术公司到全球领先的制药公司）合作。该公司收集了一系列特许权使用费，使他们有权直接基于许多行业领先疗法的顶线销售进行付款，包括Imbruvica，Januvia，Kalydeco，Trikafta，Truvada，Tysabri和Xtandi。该公司直接或间接地为生物制药行业中的创新提供资金,当他们与公司合作共同资助后期临床试验和新产品上市以换取未来的特许权使用费时，以及当他们从原始创新者那里获得现有的特许权使用费时，就间接地为生物制药行业的创新提供资金。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.043705},{"month":2,"riseRate":0.5,"avgChangeRate":0.021545},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016917},{"month":4,"riseRate":0.666667,"avgChangeRate":0.014628},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.014335},{"month":6,"riseRate":0.666667,"avgChangeRate":0.007649},{"month":7,"riseRate":0.714286,"avgChangeRate":0.000812},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.008015},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.039169},{"month":10,"riseRate":0.5,"avgChangeRate":0.004655},{"month":11,"riseRate":0.833333,"avgChangeRate":0.044456},{"month":12,"riseRate":0.5,"avgChangeRate":0.005959}],"exchange":"NASDAQ","name":"Royalty Pharma plc","nameEN":"Royalty Pharma plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Royalty Pharma plc(RPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Royalty Pharma plc(RPRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Royalty Pharma plc,RPRX,Royalty Pharma plc股票,Royalty Pharma plc股票老虎,Royalty Pharma plc股票老虎国际,Royalty Pharma plc行情,Royalty Pharma plc股票行情,Royalty Pharma plc股价,Royalty Pharma plc股市,Royalty Pharma plc股票价格,Royalty Pharma plc股票交易,Royalty Pharma plc股票购买,Royalty Pharma plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Royalty Pharma plc(RPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Royalty Pharma plc(RPRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}